KR20240013128A - 발기부전을 치료하기 위한 제제 및 방법 - Google Patents

발기부전을 치료하기 위한 제제 및 방법 Download PDF

Info

Publication number
KR20240013128A
KR20240013128A KR1020237040722A KR20237040722A KR20240013128A KR 20240013128 A KR20240013128 A KR 20240013128A KR 1020237040722 A KR1020237040722 A KR 1020237040722A KR 20237040722 A KR20237040722 A KR 20237040722A KR 20240013128 A KR20240013128 A KR 20240013128A
Authority
KR
South Korea
Prior art keywords
vardenafil
formulation
organic
solubility
sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040722A
Other languages
English (en)
Korean (ko)
Inventor
모세 차우
셰릴 엘. 차우
Original Assignee
스트러티직 드러그 솔루션즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스트러티직 드러그 솔루션즈, 인크. filed Critical 스트러티직 드러그 솔루션즈, 인크.
Publication of KR20240013128A publication Critical patent/KR20240013128A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237040722A 2020-05-26 2021-12-01 발기부전을 치료하기 위한 제제 및 방법 Pending KR20240013128A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063029881P 2020-05-26 2020-05-26
PCT/US2021/034334 WO2021242913A1 (en) 2020-05-26 2021-05-26 Formulations and methods for treating erectile dysfunction
USPCT/US2021/034334 2021-05-26
PCT/US2021/061488 WO2022250731A1 (en) 2020-05-26 2021-12-01 Formulations and methods for treating erectile dysfunction

Publications (1)

Publication Number Publication Date
KR20240013128A true KR20240013128A (ko) 2024-01-30

Family

ID=78722740

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040722A Pending KR20240013128A (ko) 2020-05-26 2021-12-01 발기부전을 치료하기 위한 제제 및 방법

Country Status (10)

Country Link
US (1) US20240216383A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157449A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521765A (cg-RX-API-DMAC7.html)
KR (1) KR20240013128A (cg-RX-API-DMAC7.html)
CN (1) CN116568289A (cg-RX-API-DMAC7.html)
AU (1) AU2021280285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024098A2 (cg-RX-API-DMAC7.html)
CA (1) CA3179630A1 (cg-RX-API-DMAC7.html)
IL (1) IL298432A (cg-RX-API-DMAC7.html)
WO (2) WO2021242913A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL247528B1 (pl) * 2023-04-08 2025-07-21 Sativa Med Spolka Akcyjna Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20060207596A1 (en) * 2005-03-18 2006-09-21 Fairfield Clinical Trials, Llc Device and method for delivery of combination nasal medication
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MX2010004265A (es) * 2007-10-19 2010-07-28 Innozen Inc Composicion para administrar un ingrediente activo y metodo para hacer y usar el mismo.
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
US20140271847A1 (en) * 2013-03-13 2014-09-18 SatisPharma, LLC Formulations and methods for rapid penile erections
US20170014417A1 (en) * 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
CN111655229A (zh) 2017-12-20 2020-09-11 卡里亚制药控股有限公司 包含伐地那非的薄膜制剂、其制备方法及其用途
CA3105187A1 (en) * 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs

Also Published As

Publication number Publication date
IL298432A (en) 2023-01-01
CA3179630A1 (en) 2021-12-02
BR112022024098A2 (pt) 2023-02-07
CN116568289A (zh) 2023-08-08
JP2024521765A (ja) 2024-06-04
WO2021242913A1 (en) 2021-12-02
US20240216383A1 (en) 2024-07-04
EP4157449A4 (en) 2024-05-29
EP4157449A1 (en) 2023-04-05
WO2022250731A1 (en) 2022-12-01
AU2021280285A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
ES2620413T3 (es) Formulaciones veterinarias antihelmínticas tópicas
BG64372B1 (bg) Фармацевтична форма за интраназално приложение за лечение на еректилна дисфункция при мъжете или женски сексуални смущения
JP2018516989A (ja) ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
ZA200407672B (en) Low dose liquid entecavir formulations and use.
US20250345458A1 (en) Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
CA2391968A1 (en) An improved pharmaceutical composition for treating male erectile dysfunction
WO2022250731A1 (en) Formulations and methods for treating erectile dysfunction
EP2086524B1 (en) Transnasal anticonvulsive pharmaceutical composition
WO2012137054A1 (en) Pharmaceutical composition containing cyclobenzaprine suitable to intranasal administration
US12324811B2 (en) Intranasal formulation
HK40098632A (en) Formulations and methods for treating erectile dysfunction
Park et al. Can currently available drugs for erectile dysfunction be re-formulated to achieve rapid effect?
JP2016540748A (ja) オンダンセトロン舌下スプレー製剤
WO2023108074A1 (en) Novel salvinorin compositions
ES2378374T3 (es) Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
US20050075371A1 (en) Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2026043819A1 (en) Formulations and methods for convenient and rapid diuresis for the treatment of edema
WO2022123433A1 (en) Oral pharmaceutical compositions of remdesivir
JP2017523231A (ja) 癌治療用アファチニブ医薬キット
JP2022501407A (ja) ゾルピデム又はその薬学的に許容される塩の口腔粘膜溶液剤
HK1081075B (en) Topical anthelmintic veterinary formulations

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231125

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241129

Comment text: Request for Examination of Application